The abstract is read at the publisher; the summary is JClub's.
Adjuvant S-1 after resection for biliary tract cancer yields sustained 5-year overall survival of 64% versus 52% with observation (HR 0.72, one-sided P=.01).
- Why it matters: The trial addressed whether the early 3-year survival advantage of adjuvant S-1 in resected biliary tract cancer persists with longer follow-up.
- What they did: In a multicenter, open-label randomized phase III trial in Japan, 440 resected biliary tract cancer patients received either observation (n=222) or S-1 (n=218) for four cycles, with OS as the primary endpoint.
- The result: With median follow-up of 61.5 months, S-1 improved overall survival (median 8.2 vs 5.9 years) and showed relapse-free survival of 3.5 vs 6.1 years, supporting standard use.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.